Oral mesalamine and clinical remission are associated with a decrease in the extent of long-standing ulcerative colitis
β Scribed by Michael F. Picco; Murli Krishna; John R. Cangemi; Donna Shelton
- Book ID
- 110087079
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 217 KB
- Volume
- 12
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Background: Mesalamine is the first-line drug for the treatment of ulcerative colitis (UC). We directly compared the efficacy and safety of two mesalamine formulations for the induction of remission in patients with UC. ## Methods: In a multicenter, double-blind, randomized study, 229 patients wit
Background: Mesalamine has been used as the first-line medication for the treatment of ulcerative colitis (UC). We directly compared the efficacy and safety of two different mesalamine formulations in the maintenance of remission in patients with UC. ## Methods: In a multicenter, double-blind, ran